Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes.

CONCLUSION: The present study suggests that switching DPP-4 inhibitors to tofogliflozin ameliorates arterial stiffness in T2DM patients partly via improvement of liver function. Baseline serum levels of AGEs may identify patients who more improve arterial stiffness by the treatment with tofogliflozin. PMID: 29766812 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29766812?dopt=Abstract

Source: Current Vascular Pharmacology - May 15, 2018 Category: Drugs & Pharmacology Authors: Tahara N, Yamagish SI, Bekki M, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y Tags: Curr Vasc Pharmacol Source Type: research